| Dr Daniel Marancenbaum, MD | |
|
3917 West Rd Ste 250, Los Alamos, NM 87544-5302 | |
| (505) 661-9201 | |
| (505) 661-9185 |
| Full Name | Dr Daniel Marancenbaum |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 24 Years |
| Location | 3917 West Rd Ste 250, Los Alamos, New Mexico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790937068 | NPI | - | NPPES |
| 80983294 | Medicaid | NM |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Las Cruces Physician Practices, Llc | 7618974858 | 75 |
News Archive
Congress will consider a new drug approval pathway to encourage development of critically needed, lifesaving antibiotics as part of a strategy to address the public health crisis of antibiotic resistance. The Infectious Diseases Society of America (IDSA) proposed the new pathway, the "Special Population Limited Medical Use (SPLMU)" mechanism, to provide an important new approval option for companies interested in developing drugs to treat patients with serious infections where few or no treatment options exist.
Sleeping helps to reinforce what we've learned. And brain scans have revealed that cerebral activity associated with learning new information is replayed during sleep.
The Wall Street Journal, CBS, and other popular news outlets have recently featured headline stories about a clinical study that is recruiting patients suffering with uterine fibroids. "We're not at all surprised by the attention this study is getting from the media," said Russ DeLonzor, President and Chief Operating Officer of Halt Medical, Inc., a medical technology company headquartered near San Francisco.
Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing novel antibiotics effective against antibiotic-resistant bacteria, presented new, positive Phase 2 clinical data on its lead drug candidate, eravacycline (TP-434), on September 11, 2012, at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.
A free, illustrated easy-to-read pamphlet that compares drugs for preventing heart attacks, heart failure or strokes in people with stable coronary heart disease is one of six new Spanish-language publications from HHS' Agency for Healthcare Research and Quality that help patients compare treatments for common illnesses.
› Verified 5 days ago
| Entity Name | Presbyterian Healthcare Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104802354 PECOS PAC ID: 9234041708 Enrollment ID: O20031103000603 |
News Archive
Congress will consider a new drug approval pathway to encourage development of critically needed, lifesaving antibiotics as part of a strategy to address the public health crisis of antibiotic resistance. The Infectious Diseases Society of America (IDSA) proposed the new pathway, the "Special Population Limited Medical Use (SPLMU)" mechanism, to provide an important new approval option for companies interested in developing drugs to treat patients with serious infections where few or no treatment options exist.
Sleeping helps to reinforce what we've learned. And brain scans have revealed that cerebral activity associated with learning new information is replayed during sleep.
The Wall Street Journal, CBS, and other popular news outlets have recently featured headline stories about a clinical study that is recruiting patients suffering with uterine fibroids. "We're not at all surprised by the attention this study is getting from the media," said Russ DeLonzor, President and Chief Operating Officer of Halt Medical, Inc., a medical technology company headquartered near San Francisco.
Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing novel antibiotics effective against antibiotic-resistant bacteria, presented new, positive Phase 2 clinical data on its lead drug candidate, eravacycline (TP-434), on September 11, 2012, at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.
A free, illustrated easy-to-read pamphlet that compares drugs for preventing heart attacks, heart failure or strokes in people with stable coronary heart disease is one of six new Spanish-language publications from HHS' Agency for Healthcare Research and Quality that help patients compare treatments for common illnesses.
› Verified 5 days ago
| Entity Name | Las Cruces Physician Practices, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093947491 PECOS PAC ID: 7618974858 Enrollment ID: O20061031000215 |
News Archive
Congress will consider a new drug approval pathway to encourage development of critically needed, lifesaving antibiotics as part of a strategy to address the public health crisis of antibiotic resistance. The Infectious Diseases Society of America (IDSA) proposed the new pathway, the "Special Population Limited Medical Use (SPLMU)" mechanism, to provide an important new approval option for companies interested in developing drugs to treat patients with serious infections where few or no treatment options exist.
Sleeping helps to reinforce what we've learned. And brain scans have revealed that cerebral activity associated with learning new information is replayed during sleep.
The Wall Street Journal, CBS, and other popular news outlets have recently featured headline stories about a clinical study that is recruiting patients suffering with uterine fibroids. "We're not at all surprised by the attention this study is getting from the media," said Russ DeLonzor, President and Chief Operating Officer of Halt Medical, Inc., a medical technology company headquartered near San Francisco.
Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing novel antibiotics effective against antibiotic-resistant bacteria, presented new, positive Phase 2 clinical data on its lead drug candidate, eravacycline (TP-434), on September 11, 2012, at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.
A free, illustrated easy-to-read pamphlet that compares drugs for preventing heart attacks, heart failure or strokes in people with stable coronary heart disease is one of six new Spanish-language publications from HHS' Agency for Healthcare Research and Quality that help patients compare treatments for common illnesses.
› Verified 5 days ago
| Entity Name | Los Alamos Physician Practices Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750330510 PECOS PAC ID: 4587661541 Enrollment ID: O20061104000041 |
News Archive
Congress will consider a new drug approval pathway to encourage development of critically needed, lifesaving antibiotics as part of a strategy to address the public health crisis of antibiotic resistance. The Infectious Diseases Society of America (IDSA) proposed the new pathway, the "Special Population Limited Medical Use (SPLMU)" mechanism, to provide an important new approval option for companies interested in developing drugs to treat patients with serious infections where few or no treatment options exist.
Sleeping helps to reinforce what we've learned. And brain scans have revealed that cerebral activity associated with learning new information is replayed during sleep.
The Wall Street Journal, CBS, and other popular news outlets have recently featured headline stories about a clinical study that is recruiting patients suffering with uterine fibroids. "We're not at all surprised by the attention this study is getting from the media," said Russ DeLonzor, President and Chief Operating Officer of Halt Medical, Inc., a medical technology company headquartered near San Francisco.
Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing novel antibiotics effective against antibiotic-resistant bacteria, presented new, positive Phase 2 clinical data on its lead drug candidate, eravacycline (TP-434), on September 11, 2012, at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.
A free, illustrated easy-to-read pamphlet that compares drugs for preventing heart attacks, heart failure or strokes in people with stable coronary heart disease is one of six new Spanish-language publications from HHS' Agency for Healthcare Research and Quality that help patients compare treatments for common illnesses.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Daniel Marancenbaum, MD 2055 Walsbrook, San Antonio, TX 78260-2436 Ph: (505) 695-0541 | Dr Daniel Marancenbaum, MD 3917 West Rd Ste 250, Los Alamos, NM 87544-5302 Ph: (505) 661-9201 |
News Archive
Congress will consider a new drug approval pathway to encourage development of critically needed, lifesaving antibiotics as part of a strategy to address the public health crisis of antibiotic resistance. The Infectious Diseases Society of America (IDSA) proposed the new pathway, the "Special Population Limited Medical Use (SPLMU)" mechanism, to provide an important new approval option for companies interested in developing drugs to treat patients with serious infections where few or no treatment options exist.
Sleeping helps to reinforce what we've learned. And brain scans have revealed that cerebral activity associated with learning new information is replayed during sleep.
The Wall Street Journal, CBS, and other popular news outlets have recently featured headline stories about a clinical study that is recruiting patients suffering with uterine fibroids. "We're not at all surprised by the attention this study is getting from the media," said Russ DeLonzor, President and Chief Operating Officer of Halt Medical, Inc., a medical technology company headquartered near San Francisco.
Tetraphase Pharmaceuticals, Inc., a clinical-stage life science company developing novel antibiotics effective against antibiotic-resistant bacteria, presented new, positive Phase 2 clinical data on its lead drug candidate, eravacycline (TP-434), on September 11, 2012, at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.
A free, illustrated easy-to-read pamphlet that compares drugs for preventing heart attacks, heart failure or strokes in people with stable coronary heart disease is one of six new Spanish-language publications from HHS' Agency for Healthcare Research and Quality that help patients compare treatments for common illnesses.
› Verified 5 days ago
Patricia Combs, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 3917 West Rd, Suite 250, Los Alamos, NM 87544 Phone: 505-662-4412 | |
Christine Carlos, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 3917 West Rd, Suite 250, Los Alamos, NM 87544 Phone: 505-662-4412 | |
Danielle Duquette Bridge, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3917 West Rd, Los Alamos, NM 87544 Phone: 509-881-8513 |